| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Resignation/termination of a director |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/25/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/19/2023 |
4
| van den Broek Richard (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Granted 3,750 shares
@ $0
Exercised 3,750 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Thorp Clay (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Humphries William D. (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 2,538 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| HARRIGAN EDMUND (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Loewy Caroline M (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Hutson Nancy J (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/16/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/24/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.1% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/25/2023 |
8-K
| Termination of a Material Definitive Agreement, Other Events Interactive Data |
| 01/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, F... |
| 12/23/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 12/21/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/31/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/27/2022 |
8-K
| Other Events Interactive Data |
|